Debate Continues on TAVI Choice for Women With Small Annuli tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
Open Stent Solution closes €2 5M Seed financing round for its breakthrough open-stent TMVR device prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
May 21, 2021
Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR.
On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement aimed at addressing this clinical niche.
All three are manufactured by Edwards Lifesciences:
Thirty-day data from TRISCEND make the case for valve replacement, specifically with the Evoque device, in patients with symptomatic and at least moderate TR.